These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 27848940)

  • 1. Parenteral iron polymaltose changes i:c-terminal FGF23 ratios in iron deficiency, but not in dialysis patients.
    Tan SJ; Satake S; Smith ER; Toussaint ND; Hewitson TD; Holt SG
    Eur J Clin Nutr; 2017 Feb; 71(2):180-184. PubMed ID: 27848940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of intravenous iron on fibroblast growth factor 23 (FGF23) in haemodialysis patients: a randomized controlled trial.
    Roberts MA; Huang L; Lee D; MacGinley R; Troster SM; Kent AB; Bansal SS; Macdougall IC; McMahon LP
    BMC Nephrol; 2016 Nov; 17(1):177. PubMed ID: 27852236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women.
    Wolf M; Koch TA; Bregman DB
    J Bone Miner Res; 2013 Aug; 28(8):1793-803. PubMed ID: 23505057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relation between Red Cell Distribution Width and Fibroblast Growth Factor 23 Cleaving in Patients with Chronic Kidney Disease and Heart Failure.
    van Breda F; Emans ME; van der Putten K; Braam B; van Ittersum FJ; Kraaijenhagen RJ; de Borst MH; Vervloet M; Gaillard CA
    PLoS One; 2015; 10(6):e0128994. PubMed ID: 26079688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral iron supplementation with sodium ferrous citrate reduces the serum intact and c-terminal fibroblast growth factor 23 levels of maintenance haemodialysis patients.
    Yamashita K; Mizuiri S; Nishizawa Y; Kenichiro S; Doi S; Masaki T
    Nephrology (Carlton); 2017 Dec; 22(12):947-953. PubMed ID: 27558654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Associations Between Intravenous Iron, Inflammation and FGF23 in Non-Dialysis Patients with Chronic Kidney Disease Stages 3-5.
    Muras-Szwedziak K; Nowicki M
    Kidney Blood Press Res; 2018; 43(1):143-151. PubMed ID: 29444509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral Versus Intravenous Iron Supplementation for the Treatment of Iron Deficiency Anemia in Patients on Maintenance Hemodialysis-Effect on Fibroblast Growth Factor-23 Metabolism.
    Fukao W; Hasuike Y; Yamakawa T; Toyoda K; Aichi M; Masachika S; Kantou M; Takahishi SI; Iwasaki T; Yahiro M; Nanami M; Nagasawa Y; Kuragano T; Nakanishi T
    J Ren Nutr; 2018 Jul; 28(4):270-277. PubMed ID: 29703633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphate control in reducing FGF23 levels in hemodialysis patients.
    Rodelo-Haad C; Rodríguez-Ortiz ME; Martin-Malo A; Pendon-Ruiz de Mier MV; Agüera ML; Muñoz-Castañeda JR; Soriano S; Caravaca F; Alvarez-Lara MA; Felsenfeld A; Aljama P; Rodriguez M
    PLoS One; 2018; 13(8):e0201537. PubMed ID: 30086150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C-Terminal Fibroblast Growth Factor 23, Iron Deficiency, and Mortality in Renal Transplant Recipients.
    Eisenga MF; van Londen M; Leaf DE; Nolte IM; Navis G; Bakker SJL; de Borst MH; Gaillard CAJM
    J Am Soc Nephrol; 2017 Dec; 28(12):3639-3646. PubMed ID: 28774998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Administration of Ferric Citrate Hydrate Decreases Circulating FGF23 Levels Independently of Serum Phosphate Levels in Hemodialysis Patients with Iron Deficiency.
    Iguchi A; Kazama JJ; Yamamoto S; Yoshita K; Watanabe Y; Iino N; Narita I
    Nephron; 2015; 131(3):161-6. PubMed ID: 26551233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alterations in regulators of the renal-bone axis, inflammation and iron status in older people with early renal impairment and the effect of vitamin D supplementation.
    Christodoulou M; Aspray TJ; Piec I; Fraser WD; Schoenmakers I;
    Age Ageing; 2024 May; 53(5):. PubMed ID: 38770543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of ferric citrate hydrate on fibroblast growth factor 23 and platelets in non-dialysis-dependent chronic kidney disease and non-chronic kidney disease patients with iron deficiency anemia.
    Ito K; Akizawa T; Arita K; Mitobe Y; Komatsu N
    Clin Exp Nephrol; 2024 Jul; 28(7):636-646. PubMed ID: 38402503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of acute kidney injury and chronic hypoxemia on fibroblast growth factor 23 levels in pediatric cardiac surgery patients.
    Hanudel MR; Wesseling-Perry K; Gales B; Ramos G; Campbell V; Ethridge K; Scotti M; Elashoff DA; Alejos J; Reemtsen B; Salusky IB
    Pediatr Nephrol; 2016 Apr; 31(4):661-9. PubMed ID: 26525200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Saccharated ferric oxide attenuates haematopoietic response induced by epoetin beta pegol in patients undergoing haemodialysis.
    Iwasaki T; Fujimori A; Nakanishi T; Okada S; Hanawa N; Hasuike Y; Kuragano T
    BMC Nephrol; 2021 Apr; 22(1):124. PubMed ID: 33832448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of ferric citrate hydrate on FGF23 and PTH levels in patients with non-dialysis-dependent chronic kidney disease with normophosphatemia and iron deficiency.
    Iguchi A; Yamamoto S; Yamazaki M; Tasaki K; Suzuki Y; Kazama JJ; Narita I
    Clin Exp Nephrol; 2018 Aug; 22(4):789-796. PubMed ID: 29181658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study.
    Schouten BJ; Hunt PJ; Livesey JH; Frampton CM; Soule SG
    J Clin Endocrinol Metab; 2009 Jul; 94(7):2332-7. PubMed ID: 19366850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma fibroblast growth factor 23 concentration and iron status. Does the relationship exist in the elderly population?
    Bożentowicz-Wikarek M; Kocełak P; Owczarek A; Olszanecka-Glinianowicz M; Mossakowska M; Skalska A; Więcek A; Chudek J
    Clin Biochem; 2015 Apr; 48(6):431-6. PubMed ID: 25583093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential Impacts of Intravenous Iron Administration and Iron-Containing Phosphate Binders on Serum Intact Fibroblast Growth Factor 23 Levels.
    Honda H; Tanaka K; Michihata T; Shibagaki K; Yuza T; Hirao K; Tomosugi N; Shibata T
    Blood Purif; 2019; 47 Suppl 2():63-69. PubMed ID: 30943476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of ferric carboxymaltose on markers of mineral and bone metabolism: A single-center prospective observational study of women with iron deficiency.
    Frazier R; Hodakowski A; Cai X; Lee J; Zakarija A; Stein B; David V; Wolf M; Isakova T; Mehta R
    Bone; 2020 Dec; 141():115559. PubMed ID: 32730929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of ferric citrate on serum phosphate and fibroblast growth factor 23 among patients with nondialysis-dependent chronic kidney disease: path analyses.
    Block GA; Pergola PE; Fishbane S; Martins JG; LeWinter RD; Uhlig K; Neylan JF; Chertow GM
    Nephrol Dial Transplant; 2019 Jul; 34(7):1115-1124. PubMed ID: 30380116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.